Hiroaki Yasumoto

Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 41 publications

Risk classification by pathological and biochemical prognostic factors determined by extensive exploration for metastatic hormone sensitive prostate cancer.

Risk classification by pathological and biochemical prognostic factors determined by extensive exploration for metastatic hormone sensitive prostate cancer.

Journal: World journal of urology

Published: November 11, 2024

Improved prognosis of de novo metastatic prostate cancer after an introduction of life-prolonging agents for castration-resistant prostate cancer.

Improved prognosis of de novo metastatic prostate cancer after an introduction of life-prolonging agents for castration-resistant prostate cancer.

Journal: International journal of clinical oncology

Published: September 17, 2024

A Case of Chromophobe Renal Cell Carcinoma Producing Interleukin-6 with Stauffer Syndrome

A Case of Chromophobe Renal Cell Carcinoma Producing Interleukin-6 with Stauffer Syndrome

Journal: Hinyokika kiyo. Acta urologica Japonica

Published: September 05, 2023

Second-line Pembrolizumab for Metastatic Urothelial Carcinoma: Differences in Treatment Outcomes According to the Primary Site.

Second-line Pembrolizumab for Metastatic Urothelial Carcinoma: Differences in Treatment Outcomes According to the Primary Site.

Journal: Anticancer research

Published: July 19, 2023

Correction: CYP1B1 promotes tumorigenesis via altered expression of CDC20 and DAPK1 genes in renal cell carcinoma.

Correction: CYP1B1 promotes tumorigenesis via altered expression of CDC20 and DAPK1 genes in renal cell carcinoma.

Journal: BMC cancer

Published: July 25, 2022

Site-specific Risk Stratification Models for Postoperative Recurrence and Survival Prediction in Patients with Upper Tract Urothelial Carcinoma Undergoing Radical Nephroureterectomy: Better Stratification for Adjuvant Therapy.

Site-specific Risk Stratification Models for Postoperative Recurrence and Survival Prediction in Patients with Upper Tract Urothelial Carcinoma Undergoing Radical Nephroureterectomy: Better Stratification for Adjuvant Therapy.

Journal: European urology open science

Published: May 06, 2022

Efficacy of combined androgen blockade therapy in patients with metastatic hormone-sensitive prostate cancer stratified by tumor burden.

Efficacy of combined androgen blockade therapy in patients with metastatic hormone-sensitive prostate cancer stratified by tumor burden.

Journal: International journal of urology : official journal of the Japanese Urological Association

Published: August 21, 2021

Impact of prior intravesical bacillus Calmette-Guerin therapy on the effectiveness of pembrolizumab for patients with metastatic urothelial carcinoma.

Impact of prior intravesical bacillus Calmette-Guerin therapy on the effectiveness of pembrolizumab for patients with metastatic urothelial carcinoma.

Journal: Urologic oncology

Published: May 24, 2021

Novel metastatic burden-stratified risk model in de novo metastatic hormone-sensitive prostate cancer.

Novel metastatic burden-stratified risk model in de novo metastatic hormone-sensitive prostate cancer.

Journal: Cancer science

Published: April 16, 2021

Impact of histological variants on outcomes in patients with urothelial carcinoma treated with pembrolizumab: a propensity score matching analysis.

Impact of histological variants on outcomes in patients with urothelial carcinoma treated with pembrolizumab: a propensity score matching analysis.

Journal: BJU international

Published: March 09, 2021

Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer outcomes in patients without radical cystectomy.

Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer outcomes in patients without radical cystectomy.

Journal: International journal of clinical oncology

Published: March 01, 2021

Risk stratification for the prognosis of patients with chemoresistant urothelial cancer treated with pembrolizumab.

Risk stratification for the prognosis of patients with chemoresistant urothelial cancer treated with pembrolizumab.

Journal: Cancer science

Published: November 09, 2020

Showing 1-12 of 41

Last Updated: 09/26/2026